Literature DB >> 19595437

Premature vascular damage in systemic lupus erythematosus: an imbalance of damage and repair?

Mariana J Kaplan1.   

Abstract

Systemic lupus erythematosus (SLE) is associated with an increase in the risk of premature cardiovascular complications caused by accelerated atherosclerosis, which significantly contributes to morbidity and mortality. Standard Framingham risk factors seem to be less important predictors of cardiovascular events than the presence of active SLE, and the immune dysregulation characteristic of lupus seems to play a dominant role in atherogenesis. Although both SLE-specific and nonspecific mechanisms have been proposed to play a prominent role in the induction of premature vascular damage in this disease, the exact etiology remains unclear. This review summarizes some of the proposed mechanisms that may promote accelerated vascular damage in lupus and explores potential targets for cardiovascular risk prevention in this patient population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19595437     DOI: 10.1016/j.trsl.2009.05.005

Source DB:  PubMed          Journal:  Transl Res        ISSN: 1878-1810            Impact factor:   7.012


  3 in total

1.  IFN-α Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus.

Authors:  Joy Jones Buie; Ludivine L Renaud; Robin Muise-Helmericks; Jim C Oates
Journal:  J Immunol       Date:  2017-08-04       Impact factor: 5.422

Review 2.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

3.  Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRβ, chemotaxis and TNFα production.

Authors:  Brian J Skaggs; Bevra H Hahn; Lori Sahakian; Jennifer Grossman; Maureen McMahon
Journal:  Clin Immunol       Date:  2010-07-15       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.